After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of ...

At AACR, first‑in‑human KIR‑CAR T data show early activity in solid tumors and introduce a novel design aimed at limiting T ...

Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...

Researchers are advancing CAR T-cell therapy for solid tumors using armored cells that deliver IL-36γ. Expanded manufacturing capabilities are accelerating development, bringing next-generation cell ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic ...

Eli Lilly and Company (NYSE: LLY) and Kelonia Therapeutics, Inc. ("Kelonia"), a clinical-stage biotechnology company ...

The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen ...

Chimeric antigen receptor, or CAR, therapy is no longer just a cancer story. This review shows how the field is expanding beyond conventional CAR-T cells into a wider family of engineered cell ...

Verismo Therapeutics, the U.S. subsidiary of HLB Innovation, said it will unveil a CAR-T cell technology to treat solid tumors at the American Association for Cancer Research on the 20th (local time).

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...

Eli Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, in a deal that would bolster the buyer’s oncology ...